Carmen Waengler

Learn More
OBJECTIVE—Noninvasive determination of pancreatic ␤-cell mass in vivo has been hampered by the lack of suitable ␤-cell– specific imaging agents. This report outlines an approach for the development of novel ligands homing selectively to islet cells in vivo. RESEARCH DESIGN AND METHODS—To generate agents specifically binding to pancreatic islets, a phage(More)
Molecular imaging-and especially Positron Emission Tomography (PET)-is of increasing importance for the diagnosis of various diseases and thus is experiencing increasing dissemination. Consequently, there is a growing demand for appropriate PET tracers which allow for a specific accumulation in the target structure as well as its visualization and exhibit(More)
Silicon-[ 18 F]fluorine (Si-18 F) radiochemistry has recently emerged alongside other unconventional approaches such as aluminum-18 F and boron-18 F based labeling strategies, reshaping the landscape of modern 18 F-radiochemistry. All these novel methodologies are driven by the demand for more convenient 18 F-labeling procedures to further disseminate one(More)
BACKGROUND Over the recent years, radiopharmaceutical chemistry has experienced a wide variety of innovative pushes towards finding both novel and unconventional radiochemical methods to introduce fluorine-18 into radiotracers for positron emission tomography (PET). These "nonclassical" labeling methodologies based on silicon-, boron-, and aluminium-(18)F(More)
Molecular imaging--and especially positron emission tomography (PET)--has gained increasing importance for diagnosis of various diseases and thus experiences an increasing dissemination. Therefore, there is also a growing demand for highly affine PET tracers specifically accumulating and visualizing target structures in the human body. Beyond the(More)
For many years, the main application of [(18)F]F-DOPA has been the PET imaging of neuropsychiatric diseases, movement disorders, and brain malignancies. Recent findings however point to very favorable results of this tracer for the imaging of other malignant diseases such as neuroendocrine tumors, pheochromocytoma, and pancreatic adenocarcinoma expanding(More)
OBJECTIVES Receptor scintigraphy gains more interest for diagnosis and treatment of tumors, in particular for neuroendocrine tumors (NET). We used a pan-Bombesin analog, the peptide DOTA-PEG2-[D-tyr6, β-Ala11, Thi13, Nle14] BN(6-14) amide (BZH3). BZH3 binds to at least three receptor subtypes: the BB1 (Neuromedin B), BB2 (Gastrin-releasing peptide, GRP),(More)
sulfoxide were all purchased from Aldrich and were used as received. Potassium carbonate (Caledon), chloroform-d6 (Cambridge Isotope Laboratories) were also used as received. Highly enriched [ 18 O]water (>97%) was purchased from Rotem. Light Cartridge, Sep-Pak Silica Light Cartridge) were purchased from Waters (USA). SiFA-OH(2) was synthesised as per(More)
The synthesis, radiolabeling and in vitro evaluation of new silicon-fluoride acceptor (SiFA) derivatized D(2)-receptor ligands is reported. The SiFA-technology simplifies the introduction of fluorine-18 into target specific biomolecules for Positron-Emission-Tomography (PET). However, one of the remaining challenges, especially for small molecules such as(More)
BACKGROUND Radiation-induced nephropathy is still dose limiting in radionuclide therapy of neuroendocrine tumors. We investigated the nephroprotective potential of the angiotensine converting enzyme inhibiting drug enalpril after [177Lu]-DOTATATE therapy in a murine model of radiation-induced nephropathy by renal scintigraphy. At first, the appropriate(More)